PT-141 (Bremelanotide) + CJC-1295 Stack: Complete Protocol

What Are PT-141 and CJC-1295 and Why Stack Them?

PT-141, sold under the brand name Vyleesi, is a synthetic melanocortin agonist. The FDA approved it in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women at a 1.75 mg subcutaneous dose [1]. CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) that carries a drug-affinity-complex (DAC) modification, extending its plasma half-life from minutes to approximately 6 to 8 days [2].

The logic behind combining them is straightforward: the two peptides work on entirely different receptor systems and produce non-overlapping effects. PT-141 acts centrally on melanocortin-3 and melanocortin-4 receptors (MC3R, MC4R) to generate sexual desire and arousal regardless of vascular status [3]. CJC-1295 amplifies pulsatile GH secretion, which raises IGF-1 and supports lean mass, recovery, and connective tissue remodeling [4].

Why the Two Axes Matter Clinically

Sexual dysfunction and suboptimal body composition frequently coexist in adults with relative GH deficiency or age-related hormonal decline. A 2013 analysis in the Journal of Clinical Endocrinology and Metabolism documented that GH deficiency correlates with impaired libido and sexual function in both sexes, independently of testosterone [5]. Addressing GH pulsatility with CJC-1295 while simultaneously activating melanocortin arousal pathways with PT-141 may produce additive benefit, though no RCT has tested this pairing.

Evidence Quality Rating for This Stack

Practitioners and patients should understand the evidence hierarchy here. PT-141 has Phase 2 and Phase 3 RCT support as a standalone agent [1,3]. CJC-1295 has Phase 1 and Phase 2 data from Teichman et al. (2006) showing dose-dependent GH and IGF-1 elevations [2]. The combination carries no published controlled trial data. Every protocol element below is synthesized from mechanism, single-agent trials, pharmacokinetic modeling, and structured clinician-reported outcomes.

How PT-141 (Bremelanotide) Works

PT-141 is a cyclic heptapeptide derived from the alpha-melanocyte-stimulating hormone (alpha-MSH) analog melanotan II. Unlike PDE5 inhibitors such as sildenafil, which act peripherally on vascular smooth muscle, PT-141 activates MC4R neurons in the medial preoptic area of the hypothalamus to generate the desire component of sexual response [3].

Mechanism at the Melanocortin Receptors

The melanocortin system regulates appetite, pigmentation, inflammation, and sexual behavior. MC4R activation in particular drives pro-erectile and pro-arousal signaling in animal models [6]. A 2004 study in the European Journal of Pharmacology demonstrated that selective MC4R agonism in male rats produced penile erection and increased mounting behavior at doses equivalent to 0.1 mg/kg [6]. The FDA pharmacology review for Vyleesi confirmed this central mechanism distinguishes bremelanotide from all prior sexual-dysfunction drugs [1].

Single-Agent RCT Data

The Phase 3 RECONNECT trials enrolled 1,247 premenopausal women across two parallel studies. Women using bremelanotide 1.75 mg reported a statistically significant increase in satisfying sexual events (SSE) versus placebo (P<0.001), alongside reductions in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [1]. Mean blood pressure rose by approximately 6 mmHg systolic and 3 mmHg diastolic within one hour of injection and returned to baseline within 12 hours [1].

Off-Label Use in Men

The FDA approval covers premenopausal women only. Off-label use in men with hypoactive desire or erectile dysfunction unresponsive to PDE5 inhibitors has been reported in clinical practice, supported by earlier Phase 2 data showing dose-dependent erections in men at 4 to 10 mg intranasal doses (a route no longer in development due to blood-pressure concern) [7]. Current subcutaneous protocols in men typically use 1.0 to 2.0 mg.

How CJC-1295 Works

CJC-1295 is a 30-amino-acid GHRH analog with a maleimidoproprionic acid (MPA) side chain that covalently binds serum albumin after injection, dramatically extending its half-life. This DAC technology converts a peptide that would otherwise clear in minutes into one that sustains GH-releasing activity for days [2].

Growth Hormone Pulse Amplification

Normal adult GH secretion follows a pulsatile pattern driven by endogenous GHRH from the hypothalamus. CJC-1295 mimics and prolongs this signal. In the 2006 Phase 2 RCT by Teichman et al. (N=65 healthy adults), a single 2 mg/kg dose of CJC-1295 increased mean GH levels 2 to 10 fold over baseline and elevated IGF-1 by 30 to 50% for up to 14 days [2]. The GH pulses remained pulsatile rather than becoming supraphysiologic flatline elevations, which is the pharmacokinetic profile most practitioners consider safer than continuous GH infusion.

IGF-1 and Downstream Effects

IGF-1 mediates most of GH's anabolic effects: protein synthesis, lipolysis, collagen turnover, and neurotrophin support [4]. A Cochrane review of GH supplementation in adults with GH deficiency (27 RCTs, N=1,415) found significant improvements in lean body mass (+1.6 kg mean), fat mass reduction (−2.4 kg mean), and bone mineral density over 6 to 12 months [8]. CJC-1295 is expected to produce similar downstream effects by raising IGF-1, though direct RCT data for CJC-1295 on body composition endpoints in healthy adults remains limited [2].

CJC-1295 Without DAC vs. With DAC

Products labeled "CJC-1295 without DAC" are actually modified GRF (1-29) with a shorter half-life of 30 minutes. That formulation requires more frequent dosing (typically 3 to 4 times weekly at bedtime) to mimic natural GH pulses. The DAC version (true CJC-1295) allows once or twice weekly injection. This article covers the DAC version unless stated otherwise.

Stacking Rationale: Why These Two Peptides Together

PT-141 and CJC-1295 do not share receptor systems, metabolic pathways, or elimination routes in ways that produce pharmacokinetic interference. PT-141 reaches peak plasma concentration within 1 hour of subcutaneous injection and has a half-life of approximately 2.7 hours [1]. CJC-1295 (DAC) binds albumin and clears over 6 to 8 days [2]. There is no known competitive binding, no shared cytochrome P450 pathway, and no documented pharmacokinetic drug-drug interaction between melanocortin agonists and GHRH analogs.

The rationale is additive rather than synergistic in the pharmacological sense: one peptide addresses desire and arousal acutely; the other supports the hormonal and tissue environment chronically.

The HealthRX clinical team uses the following tiered decision framework when evaluating this stack for patients:

Tier 1 (Assessment): Confirm HSDD or male hypoactive desire; confirm suboptimal IGF-1 (reference range 115 to 307 ng/mL for ages 30 to 60 per Endocrine Society guidelines) [9]; rule out cardiovascular contraindications.

Tier 2 (Initiation): Start each agent at its minimum effective dose separately before combining. Establish PT-141 tolerability at 1.0 mg for 2 to 3 uses. Establish CJC-1295 tolerability at 1 mg weekly for 4 weeks.

Tier 3 (Combination): Combine only after Tier 2 tolerance confirmed. Monitor IGF-1 at 8 weeks; adjust CJC-1295 dose if IGF-1 exceeds 300 ng/mL.

Tier 4 (Cycling): CJC-1295 is typically run in 12-week cycles followed by a 4-week washout. PT-141 is used on-demand, no more than once every 72 hours per the Vyleesi prescribing information [1].

Complete Dosing Protocol

PT-141 Dosing

The FDA-approved dose is 1.75 mg subcutaneous, injected into the abdomen or thigh, 45 minutes before anticipated sexual activity [1]. Off-label use frequently starts at 1.0 mg to assess tolerability. The dose may be titrated to 2.0 mg if the 1.0 mg dose produces inadequate response and is well tolerated. Do not use more than once in 72 hours. Do not exceed 8 uses per month per the Vyleesi label [1].

Injection site rotation is necessary because local reactions (erythema, transient induration) occur in approximately 13% of users at the abdomen injection site [1]. Subcutaneous injection into the upper outer thigh has shown comparable bioavailability with lower local reaction rates in clinical practice, though head-to-head site-comparison data is not available in the label.

CJC-1295 (DAC) Dosing

The Teichman Phase 2 trial used doses of 30, 60, 90, and 120 mcg/kg, with the 60 mcg/kg dose (approximately 4 to 8 mg for most adults) producing the clearest IGF-1 elevation without disproportionate side effects [2]. Practitioner protocols in off-label peptide therapy typically use a more conservative 1 to 2 mg subcutaneous once weekly, injected before sleep to align with the endogenous GH surge.

Injection timing matters. GH secretion peaks during slow-wave sleep, typically 60 to 90 minutes after sleep onset [10]. Injecting CJC-1295 30 minutes before bedtime allows the peptide to begin GHRH-receptor engagement as the natural nocturnal pulse initiates, potentially amplifying that pulse more effectively than daytime dosing.

Combined Weekly Schedule Example

| Day | PT-141 | CJC-1295 | |-----|--------|-----------| | Monday | As needed (45 min before activity) | 1 to 2 mg subcutaneous before sleep | | Tuesday, Friday | As needed (max once per 72 hr) | None | | Saturday | As needed | None | | Sunday | None | None |

Repeat weekly. Run CJC-1295 for 12 weeks, then pause 4 weeks. PT-141 continues on-demand throughout, subject to the 72-hour and 8-uses-per-month limits.

Side Effects and Risk Management

PT-141 Side Effects

The most common adverse events reported in the RECONNECT Phase 3 trials were nausea (40.0%), flushing (20.4%), injection site bruising (13.0%), headache (11.3%), and transient hyperpigmentation with repeated use [1]. Nausea typically peaks 30 to 60 minutes post-injection and resolves within 2 hours. Taking a low-dose antiemetic such as ondansetron 4 mg orally 30 minutes before PT-141 injection reduces nausea in clinical practice; this is an off-label application of ondansetron.

The blood-pressure increase is the most clinically relevant risk. Patients with uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg), a history of cardiovascular disease, or high 10-year ASCVD risk should not use PT-141 [1]. The FDA label carries a specific warning against use in patients with known cardiovascular disease [1].

Focal hyperpigmentation of the face, gums, and breasts has been reported with repeated use. The Vyleesi label notes this is more common with more than 8 doses per month [1]. Patients with darker Fitzpatrick skin types may be at greater risk, though no comparative incidence data by skin type is available in the published label.

CJC-1295 Side Effects

The Teichman trial recorded flushing, headache, and injection site pain as the most common adverse events, all rated mild and transient [2]. Supraphysiologic IGF-1 elevation is the primary long-term concern. Chronically elevated IGF-1 may increase colorectal cancer risk, per epidemiologic data [11]. The Cancer Prevention Study II Nutrition Cohort found an association between IGF-1 levels in the highest quartile and colorectal cancer risk (RR 1.49, 95% CI 1.16 to 1.92) [11]. This association does not establish causation, but it supports keeping IGF-1 within reference range during CJC-1295 use.

Fluid retention, carpal tunnel symptoms, and mild joint aches are class effects of elevated GH/IGF-1 activity, reported in GH replacement studies [8]. These typically resolve with dose reduction.

Monitoring Protocol

Baseline labs before starting the stack: IGF-1, fasting insulin, HbA1c, fasting glucose, lipid panel, prolactin, blood pressure, and a complete metabolic panel. Endocrine Society clinical practice guidelines recommend IGF-1 as the primary monitoring biomarker for GH axis activity [9].

Repeat IGF-1 at 8 weeks into the CJC-1295 cycle. If IGF-1 exceeds 300 ng/mL, reduce the CJC-1295 dose by 50% and retest at 4 weeks. If IGF-1 remains elevated above 350 ng/mL, discontinue until the next cycle.

Blood pressure should be checked within 1 to 2 hours of the first PT-141 dose. Patients using any antihypertensive medication should discuss PT-141 use with their prescriber before starting.

Who Is a Candidate for This Stack?

Inclusion Criteria

Adults with documented HSDD (premenopausal women per FDA label, or men in whom PT-141 is being used off-label) who also have IGF-1 levels below the age-adjusted lower limit of normal, or who have been identified by a clinician as having relative GH insufficiency, may derive benefit from this combination. The Endocrine Society defines adult GH deficiency as a peak GH response below 3 mcg/L on stimulation testing, with IGF-1 below the age-sex-specific reference [9].

Absolute Contraindications

Cardiovascular disease (coronary artery disease, prior MI, heart failure, uncontrolled hypertension) is an absolute contraindication to PT-141 per the FDA label [1]. Active malignancy is a relative contraindication to CJC-1295 given the IGF-1 mitogenic concern. Pregnancy contraindicates both agents.

Who Should Not Stack

Patients who have not established individual tolerability to each peptide alone should not begin this combination immediately. Starting both simultaneously makes it impossible to attribute side effects to the correct agent.

Evidence Gaps and What Practitioners Should Tell Patients

No published RCT has tested PT-141 plus CJC-1295 as a combination. The protocols above are derived from:

1. FDA prescribing information for Vyleesi (bremelanotide) [1]
2. The Teichman Phase 2 CJC-1295 trial [2]
3. Melanocortin receptor pharmacology studies [3,6]
4. GH/IGF-1 physiology and Cochrane GH-replacement data [8]
5. Endocrine Society GH deficiency guidelines [9]
6. Epidemiologic IGF-1 safety data [11]

This evidence base supports mechanism plausibility and individual agent safety profiles. It does not confirm that the combination is more effective than either agent alone, or that no novel interaction exists. Patients must receive explicit informed consent that this is an off-label combination therapy with no combination-specific controlled trial data.

The FDA Adverse Event Reporting System (FAERS) contains case reports of cardiovascular events with bremelanotide; patients and clinicians can search FAERS at accessdata.fda.gov [12].

Practical Injection Technique

Both peptides require subcutaneous injection using insulin-gauge needles (28 to 31 gauge, 4 to 8 mm length). Standard technique: pinch a 1-inch fold of skin at the injection site, insert the needle at a 45-degree angle, release the skin fold, inject slowly over 5 to 10 seconds, withdraw, apply gentle pressure [13]. Rotating between the left and right abdomen, left and right outer thigh, and lateral upper arm (for CJC-1295 only, given its longer half-life and less urgent timing) reduces localized lipoatrophy.

PT-141 should be stored at room temperature (below 30°C) and used within 30 days of first use [1]. CJC-1295 lyophilized powder should be refrigerated and reconstituted with bacteriostatic water; once reconstituted, use within 28 days [2].